News

March 2, 2020March 2, 2020

Loss of Specific Gene May Help Drive Myeloma Progression, Study Finds

News

One of the most common genomic defects in multiple myeloma patients is the loss of one copy of chromosome 13, and researchers now suggest that the loss of one ... Read more

February 28, 2020February 28, 2020

CLR 131 Helps Heavily Treated Multiple Myeloma Patients, Phase 2 Data Show

News

Cellectar Biosciences’ lead candidate CLR 131 safely and effectively prevents disease progression or reduces tumors in people with hard-to-treat multiple myeloma, according to data from a Phase 2 clinical ... Read more

February 24, 2020February 24, 2020

New CAR T-cell Therapy Shows Early Promise Against Multiple Myeloma in Lab Study

News

A new CAR T-cell therapy for people with multiple myeloma has been successfully created and tested in cell-based experiments and a mouse model, a study reported. This therapy targets a protein ... Read more

February 21, 2020February 21, 2020

Xpovio May Soon Be Available in Israel and Palestinian Authority, Karyopharm Says

News

Xpovio (selinexor), a treatment for advanced multiple myeloma, may soon be available in Israel and the Palestinian Authority through Promedico, under an exclusive distribution agreement announced by the treatment’s maker, Karyopharm ... Read more

February 19, 2020February 19, 2020

Darzalex Combo Leads to Durable Responses in Patients With Advanced Multiple Myeloma, Follow-up Data Show

News

Janssen‘s Darzalex (daratumumab) in combination with Revlimid (lenalidomide) and dexamethasone continues to lead to strong and durable responses, and prolong the time until disease worsening in patients with relapsed ... Read more

February 17, 2020February 17, 2020

Kleo’s KP1237 Therapy Soon Will Enter Clinical Testing, Following FDA’s Grant of New Drug Status

News

KP1237, an experimental therapy by Kleo Pharmaceutical that harnesses the body’s natural antibodies to fight cancers, will soon enter clinical testing for multiple myeloma, now that the U.S. Food ... Read more

February 12, 2020February 12, 2020

Phase 1/2 Trial of ‘Off-the-shelf’ CAR T-cell Therapy for Multiple Myeloma to Open Soon

News

A clinical trial is soon to begin testing Precision BioSciences‘s new CAR T-cell therapy candidate, PBCAR269A, in people with relapsed or refractory multiple myeloma. The Phase 1/2a trial (NCT04171843) is expected to begin ... Read more

February 11, 2020February 14, 2020

FDA Asked to Approve Darzalex Triple Combo for Relapsed or Refractory Multiple Myeloma

News

Janssen has asked the U.S. Food and Drug Administration (FDA) to allow Darzalex (daratumumab) to also be used in combination with Kyprolis (carfilzomib) and dexamethasone to treat people with relapsed or refractory multiple myeloma ... Read more

February 10, 2020March 5, 2020

Antibiotics Prevent Fevers, Death in Newly Diagnosed Myeloma Patients, Study Says

News

Preventive treatment with the antibiotic levofloxacin can lower the incidence of fever and death in people newly diagnosed with multiple myeloma, results from a Phase 3 clinical trial suggest. ... Read more

February 7, 2020February 7, 2020

Advancing Novel Cell Therapy for Myeloma and Multiple Cancers Goal of New Partnership

News

A recent partnership between Indapta Therapeutics and Lonza is advancing the development of an off-the-shelf cell therapy designed to treat multiple types of cancers, including multiple myeloma, the companies announced. The ... Read more

Pin It on Pinterest